ライフサイエンスコーパス: fluconazole

1 s ranged from 96.9% (voriconazole) to 98.6% (fluconazole).

2 buprofen) to not degradable (chlorthalidone, fluconazole).

3 days, followed by consolidation therapy with fluconazole.

4 exhibited >/=4-fold increases in the MICs to fluconazole.

5 es) and 44 isolates of C. neoformans against fluconazole.

6 unds that synergize with the antifungal drug fluconazole.

7 mphotericin B deoxycholate, flucytosine, and fluconazole.

8 8% of C. glabrata isolates were resistant to fluconazole.

9 , L-NMMA, and, to a larger extent, by L-NMMA+fluconazole.

10 resistant or dose-dependently susceptible to fluconazole.

11 labrata, which has reduced susceptibility to fluconazole.

12 s tested in a double-blind study versus oral fluconazole.

13 ial; 26 were treated with Sb(v), and 27 with fluconazole.

14 athogens that are intrinsically resistant to fluconazole.

15 ients treated with either an echinocandin or fluconazole.

16 ncluding potassium iodide, itraconazole, and fluconazole.

17 n Candida glabrata against anidulafungin and fluconazole.

18 n antifungal therapy with amphotericin B and fluconazole.

19 ucytosine, and $44 605 for amphotericin plus fluconazole.

20 ays for sequestration of the antifungal drug fluconazole.

21 tion (r) of zone diameters was strongest for fluconazole (0.69) and amphotericin (0.70) and moderate

22 earson correlation of MICs was strongest for fluconazole (0.94) and caspofungin (0.88).

23 age of susceptible isolates) was as follows: fluconazole, 1/4 (94.8%); voriconazole, 0.03/0.12 (98.6%

24 With fluconazole 1200 mg/d therapy, 68% of meningitis patient

25 cribed drug (260 patients [50%]) followed by fluconazole (148 [29%]) and itraconazole (93 [18%]).

26 in MICs obtained by Etest was determined for fluconazole (21 isolates), voriconazole (28 isolates), a

27 %), topical amphotericin B (1mg/ml), topical fluconazole (2mg/ml) and oral ketoconazole (200mg).

28 mpairment did not differ between the groups (fluconazole, 31% [95% CI, 21%-41%] vs placebo, 27% [95%

29 ak points, 93% of isolates were resistant to fluconazole, 35% to amphotericin B, and 7% to echinocand

30 Cs) for amphotericin B (2.6 +/- 3.5 mug/mL), fluconazole (36.9 +/- 30.7 mug/mL), and voriconazole (1.

31 fixed-dose combination tablet), 12 weeks of fluconazole, 5 days of azithromycin, and a single dose o

32 Fluconazole (6 mg/kg of body weight) or placebo.

33 the efficacy and safety of high-dosage oral fluconazole (6.5-8.0 mg/kg/d for 28 days) versus a stand

34 tifungal therapy consisted of monotherapy of fluconazole (60%), caspofungin (24%), voriconazole (8%),

35 00 mg daily); group 3, AmB (0.7-1 mg/kg) and fluconazole (600 mg twice daily); and group 4, AmB (0.7-

36 times daily); group 2, AmB (0.7-1 mg/kg) and fluconazole (800 mg daily); group 3, AmB (0.7-1 mg/kg) a

37 mg per kilogram of body weight per day) and fluconazole (800 mg per day) for 14 days, followed by co

38 g/day) for 2 weeks; and (3) amphotericin and fluconazole (800 mg/day) for 2 weeks.

39 AmB plus fluconazole (800-1200 mg/day) represents an immediately

40 e surgical ICU were the least susceptible to fluconazole (86.3%).

41 High levels of susceptibility to both fluconazole (90.8 to 95.8%) and voriconazole (95.3 to 98

42 ed altered sphingolipid content and elevated fluconazole accumulation compared with the wild type.

43 and the disk diffusion results obtained for fluconazole after only 24 h of incubation may be used to

44 MGCD290 was synergistic with fluconazole against 55 (60%) of the 91 isolates, with po

45 Resistance was also increased for fluconazole against Candida albicans (from 2.1% to 5.7%)

46 determinations and disk diffusion testing of fluconazole against more than 11,000 clinical isolates o

47 ested whether treatment with the fungistatic fluconazole ameliorated the adverse intestinal outcome o

48 Exposure to fluconazole, an antimicrobial drug that targets ergoster

49 linear, rigid core and 3-nitrotriazole-based fluconazole analogues were synthesized as dual functioni

50 zole susceptibility is strain-dependent, and fluconazole and 5-fluorocytosine are not active.

51 s after treatment) of 22.2% (6 of 27) in the fluconazole and 53.8% (14 of 26) in the Sb(v) group (P =

52 ure was lack of resolution of fever (51% for fluconazole and 57% for placebo).

53 rence in EFA between AmB in combination with fluconazole and AmB plus 5-FC for the treatment of HIV-a

54 Combinations of 12f with fluconazole and amphotericin B at subinhibitory concentr

55 Sessile C. albicans cells were resistant to fluconazole and amphotericin B, irrespective of the medi

56 s that are resistant to the antifungal drugs fluconazole and amphotericin B.

57 a glabrata) were multidrug resistant to both fluconazole and an echinocandin.

58 with posaconazole, another antifungal agent fluconazole and an experimental inhibitor, (R)-4'-chloro

59 The EA was lower for fluconazole and C. neoformans at 86.4%.

60 reference and Vitek 2 MICs was observed for fluconazole and Candida species (94.0%).

61 zole resistance rates were low; however, the fluconazole and echinocandin coresistance among C. glabr

62 eptibilities to commonly used agents such as fluconazole and echinocandins.

63 r with dimethyl sulfoxide as the solvent for fluconazole and flucytosine impacted the in vitro potenc

64 Synergy between fluconazole and MGCD290 was observed against 26/30 (87%)

65 sensitivity using rats exposed to fungicide (fluconazole and nystatin).

66 at were resistant to fluconazole between the fluconazole and placebo groups.

67 , reduces the number of infants treated with fluconazole and the duration of fluconazole therapy for

68 to strains of C. glabrata resistant to both fluconazole and the echinocandins are of concern and pro

69 with the binding interactions observed with fluconazole and the natural substrate dicyclotyrosine.

70 ion and the resistance of C. parapsilosis to fluconazole and voriconazole may vary by geographic regi

71 lture bottles is a rapid and easy method for fluconazole and voriconazole susceptibility testing for

72 e East region (79.3 and 85.8% susceptible to fluconazole and voriconazole, respectively).

73 78%; P = .49) at 180 days were similar with fluconazole and voriconazole, respectively.

74 vitro susceptibilities of 9,371 isolates to fluconazole and voriconazole.

75 flow-mediated dilatation was not affected by fluconazole and was reduced by L-NMMA and L-NMMA+flucona

76 inhibitors of cytochrome P450 epoxygenases (fluconazole) and NO synthase (N(G)-monomethyl-l-arginine

77 of N(G)-monomethyl-l-arginine (L-NMMA), TEA, fluconazole, and their combination.

78 tibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Candida species an

79 e than C. glabrata isolates to itraconazole, fluconazole, and voriconazole and to have significantly

80 ut its effect on mortality and the safety of fluconazole are unknown.

81 Last, we identified the fungicide fluconazole as an inhibitor of cAMP-mediated redistribut

82 Oral fluconazole at a dosage of 6.5-8 mg/kg/d for 28 days sho

83 Oral fluconazole at a dosage of 6.5-8 mg/kg/d for 28 days sho

84 , and those in group 3 concurrently received fluconazole at a dose of 400 mg twice daily for 2 weeks.

85 The involvement of these pathways in fluconazole basal tolerance was associated with sphingol

86 kinase activity of Ypk1 are required for the fluconazole basal tolerance.

87 x 10(9) cells/L; OR, 8.7; 95% CI, 2.5-30.2), fluconazole-based induction treatment, and slow clearanc

88 on of tested isolates that were resistant to fluconazole between the fluconazole and placebo groups.

89 heating in controls (an effect diminished by fluconazole) but not in patients.

90 s for categorical agreement were highest for fluconazole by disk diffusion (0.902, standard error [SE

91 Therapeutic drug monitoring of fluconazole can be a valuable tool to detect possible un

92 ncentrations of 3 commonly used antifungals: fluconazole, caspofungin, and amphotericin B.

93 For less common species without fluconazole CBPs, the epidemiological cutoff values (ECV

94 KKY101 cells led to higher fungal load after fluconazole challenge than wild-type cells.

95 events was similar for infants who received fluconazole compared with placebo.

96 onally, we assessed the relation between the fluconazole concentration and the time to culture conver

97 The fluconazole concentration is not sufficient in pediatric

98 A higher fluconazole concentration was associated with a shorter

99 The fluconazole concentration was considered subtherapeutic

100 e correlation of clinical variables with the fluconazole concentration.

101 om January 2007 to October 2013 and for whom fluconazole concentrations were available.

102 Fluconazole decreased resting FBF in all subjects, and t

103 In contrast, fluconazole did not bind to CYP5218, voriconazole and ke

104 factors for invasive candidiasis, empirical fluconazole did not clearly improve a composite outcome

105 3]); 102.77 for NOAC use alone vs 241.92 for fluconazole (difference, 138.46 [99% CI, 80.96-195.97]);

106 One patient treated with fluconazole discontinued treatment owing to malaise, hea

107 he fluconazole trough concentration with the fluconazole dose (P <.001), weight (P = .009), and the s

108 ently recommended dose regimen, and a higher fluconazole dose is required to achieve adequate drug ex

109 I, 1.96-5.93; p = 0.027), inadequate initial fluconazole dosing (AOR, 3.31; 95% CI, 1.83-6.00; p = 0.

110 I, 1.14-1.29; p = 0.001), inadequate initial fluconazole dosing (AOR, 9.22; 95% CI, 2.15-19.79; p = 0

111 vein catheter retention, inadequate initial fluconazole dosing, and delayed administration of antifu

112 entral vein catheters and inadequate initial fluconazole dosing, were associated with increased hospi

113 tetralogy of Fallot was observed (7 cases in fluconazole-exposed pregnancies [prevalence, 0.10%] as c

114 efects overall (210 birth defects among 7352 fluconazole-exposed pregnancies [prevalence, 2.86%] and

115 From a cohort of 1,405,663 pregnancies, oral fluconazole-exposed pregnancies were compared with up to

116 The majority of fluconazole-exposed pregnancies were in women who receiv

117 risk of spontaneous abortion associated with fluconazole exposure (HR, 1.48; 95% CI, 1.23-1.77).

118 There was no significant association between fluconazole exposure and stillbirth (HR, 1.32 [95% CI, 0

119 n Denmark, we evaluated first-trimester oral fluconazole exposure and the risk of birth defects overa

120 In monospecies biofilms, fluconazole exposure favored growth of C. glabrata and C

121 Fluconazole exposure may confer an increased risk of tet

122 In addition, oral fluconazole exposure was not associated with a significa

123 Oral fluconazole exposure was not associated with an increase

124 The extensive use of fluconazole (FLC) and other azole drugs has caused the e

125 In this study, we performed a series of fluconazole (FLC) perturbation experiments for two T. as

126 Fluconazole (FLC) resistance is common in C. glabrata an

127 gal synergy of C12 and C14 with four azoles, fluconazole (FLC), itraconazole (ITC), posaconazole (POS

128 (ANF), caspofungin (CSF), micafungin (MCF), fluconazole (FLC), posaconazole (PSC), and voriconazole

129 wever, 50% of isolates that are resistant to fluconazole (FLC), the most widely used antifungal, are

130 lucytosine for at least 2 weeks, followed by fluconazole for a minimum of 8 weeks.

131 y-betaNM) is superior to the antifungal drug fluconazole for all three strains examined.

132 cies-specific clinical breakpoints (CBPs) of fluconazole for Candida (Vitek 2 AF03 yeast susceptibili

133 tococcosis between patients with and without fluconazole for primary prophylaxis of cryptococcosis.

134 ients enrolled in the 1998 clinical trial of fluconazole for the prevention of candidiasis that was p

135 amphotericin-B for those with CNS disease or fluconazole for those without.

136 sting results, we caution against the use of fluconazole for treating C. quercitrusa infections.

137 hose of C. parapsilosis for all drugs except fluconazole, for which they were significantly higher (P

138 Nineteen trials (10 with fluconazole, four with ketoconazole, one with itraconazo

139 Among 3315 women exposed to oral fluconazole from 7 through 22 weeks' gestation, 147 expe

140 Among 5382 women exposed to fluconazole from gestational week 7 to birth, 21 experie

141 tudy of critically ill children treated with fluconazole from January 2007 to October 2013 and for wh

142 candidiasis occurred less frequently in the fluconazole group (3% [95% CI, 1%-6%]) vs the placebo gr

143 quencies of adverse effects in the Sb(v) and fluconazole groups were similar, 34.6% versus 37% respec

144 Combination therapy with fluconazole had no significant effect on survival, as co

145 dida isolates tested were susceptible (S) to fluconazole; however, 13 of 31 species identified exhibi

146 The fluconazole hypersensitivity phenotype of these mutants,

147 h timely achievement of adequate exposure of fluconazole improves outcome, therapeutic drug monitorin

148 ot support the universal use of prophylactic fluconazole in extremely low-birth-weight infants.

149 ation are available, cautious prescribing of fluconazole in pregnancy may be advisable.

150 ionwide cohort study in Denmark, use of oral fluconazole in pregnancy was associated with a statistic

151 omized, blinded, placebo-controlled trial of fluconazole in premature infants.

152 Fluconazole in vitro susceptibility test results determi

153 Fluconazole in vitro susceptibility test results for 256

154 urther improved the therapeutic potential of fluconazole in vivo.

155 focus in very low birth weight infants, with fluconazole increasingly used as prophylaxis.

156 Nine patients receiving fluconazole induction therapy were reinduced with AMB pl

157 Presumed susceptibility to oral fluconazole, intravenous amphotericin B, intravitreal am

158 Fluconazole is approved by the US Food and Drug Administ

159 irst-line treatment for pregnant women, oral fluconazole is often used despite limited safety informa

160 Fluconazole is recommended as first-line treatment in in

161 Clotrimazole, fluconazole, itraconazole, ketoconazole, voriconazole an

162 s for severe or disseminated disease include fluconazole, itraconazole, or amphotericin; newer triazo

163 als (anidulafungin, caspofungin, micafungin, fluconazole, itraconazole, posaconazole, and voriconazol

164 r anidulafungin, caspofungin, 5-flucytosine, fluconazole, itraconazole, posaconazole, voriconazole, a

165 ; digoxin; verapamil; diltiazem; amiodarone; fluconazole; ketoconazole, itraconazole, voriconazole, o

166 uced flow-mediated dilatation was reduced by fluconazole, L-NMMA, and, to a larger extent, by L-NMMA+

167 inclusion criteria, reporting comparisons of fluconazole, liposomal amphotericin B (L-AmB), itraconaz

168 gin 100 mg or center-specific standard care (fluconazole, liposomal amphotericin B, or caspofungin) p

169 uconazole susceptible demonstrated a reduced fluconazole MIC that crossed an interpretive breakpoint

170 Fluconazole MICs of >/=64 mug/ml were considered resista

171 Therefore, fluconazole monotherapy is widely used in low-income and

172 ter, randomized, double-blind trial compared fluconazole (N = 295) versus voriconazole (N = 305) for

173 Primary therapy included monotherapy with fluconazole (n = 39), caspofungin (n = 16), and a polyen

174 ultivariable analysis, among HSCT recipients fluconazole nonsusceptibility was independently associat

175 or amphotericin B use; among SOT recipients, fluconazole nonsusceptibility was independently associat

176 Resistance to fluconazole occurred in 1.2% of C. albicans isolates, 5.

177 We examined the susceptibilities to fluconazole of 642 bloodstream infection (BSI) isolates

178 tal of 162 isolates (9.7%) were resistant to fluconazole, of which 98.8% were nonsusceptible to voric

179 nt role in managing stress exerted either by fluconazole or by the host environment.

180 Routine prophylaxis with fluconazole or L-AmB reduces the incidence of IFI follow

181 tes were randomly assigned to receive either fluconazole or placebo twice weekly for 42 days.

182 allogeneic HCT recipients given prophylactic fluconazole or voriconazole.

183 t reduction in the rate of IFI was seen with fluconazole (OR 0.21, CI 0.06-0.57) and L-AmB (OR 0.21,

184 echinocandin and in 15 (17.1%) treated with fluconazole (P = .730).

185 was compared with metronidazole placebo plus fluconazole placebo.

186 ic yeast Candida albicans during exposure to fluconazole plus a calcineurin inhibitor, suggesting tha

187 The activity of fluconazole plus MGCD290 was also synergistic against 6/

188 was compared with CLSI BMD method M27-A3 for fluconazole, posaconazole, and voriconazole susceptibili

189 The ECVs (expressed as mug/ml) for fluconazole, posaconazole, and voriconazole, respectivel

190 sons between the EUCAST and CLSI results for fluconazole, posaconazole, and voriconazole, respectivel

191 he combinations (MGCD290 in combination with fluconazole, posaconazole, or voriconazole) was performe

192 e activities of isavuconazole, itraconazole, fluconazole, posaconazole, voriconazole, and the three e

193 Fluconazole prophylaxis appears to be well tolerated for

194 birth weight of less than 750 g, 42 days of fluconazole prophylaxis compared with placebo did not re

195 Analysis of these studies demonstrates that fluconazole prophylaxis decreased the incidence of invas

196 C. glabrata after a 3-year period of routine fluconazole prophylaxis for selected SICU patients.

197 large, urban, academic medical center, where fluconazole prophylaxis had been utilized for approximat

198 Fluconazole prophylaxis has been shown in randomized cli

199 nated in an entire neonatal ICU by targeting fluconazole prophylaxis in infants <1000 g.

200 omized, placebo-controlled trials evaluating fluconazole prophylaxis in premature infants conducted i

201 Fluconazole prophylaxis is effective and safe in reducin

202 lonization and IC has changed in SICUs where fluconazole prophylaxis is routinely utilized has not be

203 Fluconazole prophylaxis reduced the odds of IC or death,

204 Fluconazole prophylaxis reduces candidiasis, but its eff

205 Targeting fluconazole prophylaxis to infants who are either <1000

206 Limiting fluconazole prophylaxis to infants with risk factors, in

207 xis (standard of care), 2) universal primary fluconazole prophylaxis, 3) CRAG screening with fluconaz

208 Multiple studies have been performed with fluconazole prophylaxis, including a recent multicenter

209 of invasive candidiasis may not benefit from fluconazole prophylaxis.

210 es (triazoles: cyproconazole, epoxiconazole, fluconazole, propiconazole, tebuconazole and imidazoles:

211 About 30% of fluconazole-R isolates of C. albicans, C. glabrata, C. t

212 Among the emerging fluconazole-R species were C. guilliermondii (11.4% R),

213 Seven (5%) fluconazole recipients and 10 (7%) placebo recipients ha

214 Only 44 of 122 (36%) fluconazole recipients and 48 of 127 (38%) placebo recip

215 normal liver test results occurred in 3 (2%) fluconazole recipients and 5 (4%) placebo recipients.

216 ented invasive candidiasis occurred in 5% of fluconazole recipients and 9% of placebo recipients (rel

217 da albicans was the most common organism and fluconazole remained the predominant antifungal agent us

218 ere C. glabrata (32%) and the lowest rate of fluconazole resistance (5%).

219 Prevalence of fluconazole resistance (7%) was unchanged compared with

220 dual patient during the rapid acquisition of fluconazole resistance (Flu(R)).

221 The frequencies of isolation and of fluconazole resistance among C. glabrata BSI isolates we

222 death, IC, death, Candida colonization, and fluconazole resistance among tested isolates.

223 There was no change in the proportion of fluconazole resistance between surveillance periods.

224 rata increased with patient age, the rate of fluconazole resistance declined.

225 Fluconazole resistance in C. albicans, C. tropicalis, an

226 An increase in fluconazole resistance over time was seen with C. paraps

227 patients increased the overall percentage of fluconazole resistance to 16%.

228 thopsilosis or C. metapsilosis isolates were fluconazole resistant, and all were susceptible to caspo

229 ant C. glabrata isolates from 2011, 38% were fluconazole resistant.

230 was highly active in vitro against numerous fluconazole-resistant clinical isolates of C. albicans a

231 isolates, 4 to 7 fluconazole-susceptible or fluconazole-resistant isolates from each of 5 center A p

232 ocandin-resistant strains detected among 110 fluconazole-resistant isolates of C. glabrata tested in

233 0.1-2.0 microg/ml and was also inhibitory to fluconazole-resistant isolates of Candida species.

234 Less than 30% of fluconazole-resistant isolates of Cryptococcus spp., Cry

235 There were 18 fluconazole-resistant isolates that were resistant to on

236 e or more of the echinocandins (11.1% of all fluconazole-resistant isolates), all of which contained

237 term and long-term toxicity and increases in fluconazole-resistant organisms have not been observed w

238 fibrillation, concurrent use of amiodarone, fluconazole, rifampin, and phenytoin compared with the u

239 Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin with NOACs had a si

240 he addition of TEA further reduced FBF after fluconazole, suggesting that cytochrome P450 metabolites

241 The rate of fluconazole susceptibility increased significantly from

242 23 of the 91 Candida isolates that were not fluconazole susceptible demonstrated a reduced fluconazo

243 antial difference in lipogenesis between the fluconazole-susceptible and -resistant C. albicans.

244 g to probe for metabolic differences between fluconazole-susceptible and -resistant strains at a sing

245 epidemiologically unrelated isolates, 4 to 7 fluconazole-susceptible or fluconazole-resistant isolate

246 h of 5 center A patients, 5 matched pairs of fluconazole-susceptible/resistant isolates from center B

247 Among infants receiving fluconazole, the composite primary end point of death or

248 tolerance of Cryptococcus neoformans towards fluconazole, the widely used drug for treatment of crypt

249 The patient responded to fluconazole therapy and remained asymptomatic at 2 month

250 treated with fluconazole and the duration of fluconazole therapy for each infant.

251 bicans infection by administering antifungal fluconazole therapy protected the animals from systemic

252 rough cost and scarcity of registration; and fluconazole through challenges in maintenance of local s

253 onazole and was reduced by L-NMMA and L-NMMA+fluconazole to a lesser extent than in controls.

254 s, as well as a new mechanism of suppressing fluconazole toxicity by repression of the ERG25 gene.

255 h CD4<100 cells/mcL who received pre-emptive fluconazole treatment (CRAG+ cohort) and 189 ART-naive U

256 Pre-ART CRAG screening with preemptive fluconazole treatment and improved CM treatment(s) are n

257 Fluconazole treatment decreased mucosal injury but faile

258 se reports suggest that long-term, high-dose fluconazole treatment for severe fungal infections durin

259 conazole prophylaxis, 3) CRAG screening with fluconazole treatment if antigen-positive, 4) CRAG scree

260 Fluconazole treatment in utero decreased intestinal C.al

261 egy was CRAG screening followed by high-dose fluconazole treatment of all CRAG-positive individuals.

262 of individuals initiating ART and preemptive fluconazole treatment of CrAg-positive patients resulted

263 ation of CUTS and to compare echinocandin to fluconazole treatment on CUTS outcomes.

264 Upon fluconazole treatment, Mpk1, the downstream target of PK

265 re given intra-amniotic and intra-peritoneal fluconazole treatments 2 days after intra-amniotic admin

266 independent, and positive association of the fluconazole trough concentration with the fluconazole do

267 This review will describe the history of fluconazole use for prophylaxis in infants.

268 bility was independently associated with any fluconazole use in the 3 months prior to the IFI, C. gla

269 istant organisms have not been observed with fluconazole use in the intensive care nursery.

270 malignancy (odds ratio [OR], 5.09, P = .01), fluconazole use within 30 days prior to voriconazole (OR

271 n January 2012 and May 2013 for agreement of fluconazole, voriconazole, and amphotericin B susceptibi

272 The clinical breakpoints (CBPs) for fluconazole, voriconazole, and the echinocandins have be

273 ties of 1,669 BSI isolates of C. glabrata to fluconazole, voriconazole, anidulafungin, caspofungin, a

274 breakpoints for susceptibility were used for fluconazole, voriconazole, anidulafungin, caspofungin, a

275 We determined susceptibilities to fluconazole, voriconazole, itraconazole, posaconazole, a

276 antifungal drugs that are used systemically (fluconazole, voriconazole, ketoconazole, itraconazole, a

277 We determined the in vitro activities of fluconazole, voriconazole, posaconazole, amphotericin B,

278 nst seven antifungal agents (amphotericin B, fluconazole, voriconazole, posaconazole, caspofungin, an

279 the comparison, 130 of 2823 women exposed to fluconazole vs 118 of 2823 exposed to topical azoles had

280 CI, 1.26-2.07]); 20 of 4301 women exposed to fluconazole vs 22 of 4301 exposed to topical azoles had

281 int in infants who received prophylaxis with fluconazole vs placebo was compared.

282 Overall susceptibility to fluconazole was 79.2%.

283 to susceptible [MIC, <or=8 microg/ml]) when fluconazole was combined with MGCD290 at 0.12 to 4 micro

284 ntion of 2 g of metronidazole plus 150 mg of fluconazole was compared with metronidazole placebo plus

285 Emerging resistance to fluconazole was documented among isolates of C. neoforma

286 Resistance to fluconazole was highly predictive of resistance to voric

287 Resistance to fluconazole was low among the isolates of C. albicans (0

288 Susceptibility of C. glabrata to fluconazole was lowest in the northeast region (46%) and

289 Oral fluconazole was not associated with a significantly incr

290 Fluconazole was not effective against preformed mixed- C

291 A survival benefit of amphotericin B plus fluconazole was not found.

292 ng the compounds tested, the first-line drug fluconazole was the weakest inhibitor, whereas posaconaz

293 d to inhibit K(+)(Ca) channel activation and fluconazole was used to inhibit cytochrome P450 2C9-medi

294 C. glabrata (11.9% resistant), resistance to fluconazole was very low (2.3% of isolates for C. albica

295 he PCs except acesulfame, carbamazepine, and fluconazole were attenuated along the studied river stre

296 Filled prescriptions for oral fluconazole were obtained from the National Prescription

297 eptibility of clinically important yeasts to fluconazole when using the new (lower) CBPs and ECVs.

298 the rvs161Delta mutant was more sensitive to fluconazole, whereas the rvs167Delta mutant was more res

299 may have been due to increased resistance to fluconazole, which may have developed during the chronic

300 e whether combining flucytosine or high-dose fluconazole with high-dose amphotericin B improved survi